Stanley Rose, PhD – President & CEO
Dr. Rose is a PhD biologist, seasoned biotechnology executive and serial entrepreneur. He has spent over two decades working with leading scientists and clinicians to create substantial commercial value from inventions based on genome technology.
Daniel Salomon, MD – Founding Scientific Advisor
In Memoriam, November 14, 2016
Dear Friends,
On November 10, 2016, Dr. Daniel Salomon passed away peacefully, surrounded by his loving family, following a long and courageous battle with cancer. He left behind innumerable friends and colleagues who will miss him sorely.
Dan was a brilliant physician-scientist who dedicated his professional life to the advancement of critical technologies and informatics towards improving the lives and outcomes of transplant recipients. His pioneering work in biomarker discovery and functional genomics at The Scripps Research Institute forms the basis for TGI’s core mission.
Dan was a co-Founder, Director, and the Chief Scientific Advisor of TGI, a diagnostics company commercializing non-invasive tests enabling monitoring of the immune status of transplant recipients. TGI is committed to celebrate Dan’s life and accomplishments by continuing his legacy, through our ongoing efforts to develop and provide molecular diagnostic tests that will improve transplant patient care and outcomes.
Dan was a dear friend, an amazing collaborator, and a strong business partner. We mourn Dan’s passing, but we are forever inspired by his vision.
Sincerely yours,
Dr. Stan Rose and Dr. Michael Abecassis
Dr. Salomon published more than 124 peer-reviewed manuscripts, 43 chapters and numerous reviews and edited 3 books. He served on numerous national and international committees, including Executive Board member, Program Committee Chair, Cell Transplantation Committee Chair and Xenotransplantation Committee Chair for American Society of Transplantation; Chair, National Institutes of Health Islet Cell Resources Steering Committee; Chair, NIH Genomics of Transplantation Cooperative Research Program Steering Committee; Founding Member, US Secretary of Health’s Xenotransplantation Advisory Committee; and Chair, FDA Biological Response Modifiers Advisory Committee. He also served on multiple NIH Study Sections and Special Emphasis Panels and was a member of AITC.
Dr. Salomon’s laboratory work was focused on various aspects of organ and cell transplantation and immunology with a primary focus on functional genomics, proteomics and genetics. His research objectives included discovering biomarkers for the diagnosis of acute and chronic rejection that will enable personalized management of immunosuppression; discovering prognostic markers for transplant outcomes using genetics, transcriptional profiling and proteomics; and understanding the multi-dimensionality of transcriptional regulation. These studies included microRNA regulation, alternative splicing and RNA binding proteins and the dynamic impact of epigenetic changes, both methylation and histone marking, on lymphocyte activation and differentiation into memory. He received his BS from Northwestern University and MD from Stritch-Loyola School of Medicine in Chicago. Dr. Salomon trained at Cedars-Sinai/UCLA for internal medicine and did his postdoctoral work in transplantation and immunology at Harvard Medical School. Dr. Salomon was a Founder, Director and Chief Scientific Advisor of Transplant Genomics Inc.
Dr. Peter Meintjes – Chief Commercial Officer
Dr. Meintjes joins Transplant Genomics, Inc. (TGI) after having served as CEO at Omixon, a world leader in pre-transplant HLA Typing. During his tenure at Omixon, he grew the company at a CAGR of >75% since its first full year of operation as a molecular diagnostics company. Dr. Meintjes was attracted to TGI by the unique opportunity of commercializing TGI’s flagship product; TruGraf®. In addition to successfully leading his past organization, Dr. Meintjes has technical expertise in microbiology, evolution and genetics. He holds a B.Sc, M.Sc and PhD from The University of Auckland.
Dr. John Holman – VP, Medical Affairs
Dr. Holman comes to TGI having served for the past two years as VP, Immunology and Translational Medicine, at Quark Pharmaceuticals. John has over 30 years of experience in delivery of clinical healthcare (general surgery and transplantation surgery) as well as pharmaceutical and molecular diagnostic development. Previous appointments have included serving for three years as VP Clinical Research at Myriad Genetics, and eleven years at Astellas, most recently as Executive Medical Director. Dr. Holman is a transplant surgeon by training who received his MD from the University of Texas Southwestern Medical Center at Dallas.